Alembic Pharmaceuticals Q1 FY27 Call on Aug 4, 2026

What the company has scheduled

Alembic Pharmaceuticals Limited has scheduled a meeting of its board of directors on Tuesday, August 4, 2026, to consider and approve the company’s unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). Following the board meeting, the company will host a post-results earnings conference call at 5:30 PM IST on the same day. The company said the call is intended to discuss operational and financial performance for the quarter. The disclosure was made through filings with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on July 27, 2026.

Who can attend and why it matters

The company said the session is restricted to analysts and institutional investors. Such post-results calls are typically used by investors to seek clarity on quarterly drivers, business momentum, and items within the financial statements. For Alembic, the Q1 FY27 print is pending board approval, and the company indicated that the call will follow the declaration of results. The update also sets expectations on when management interaction is scheduled, which matters for institutions tracking quarterly execution.

Two ways to join: registration or direct dial-in

Alembic outlined two options for joining the call. The first is registration through the Diamond Pass portal, which, as described by the company, sends dial-in numbers, passcodes, and a PIN to the registered email address. The second option is to join through direct dial-in using universal access numbers or toll-free lines for multiple regions. This structure is common for earnings calls, allowing both registered access and standard teleconference participation.

Dial-in details shared in the filing

The company provided universal access numbers and toll-free numbers for India and several international markets.

For further assistance, the company named Isha Lamba as the contact person, reachable at +91 22-66951652 and isha.lamba@alembic.co.in. The disclosure letter was signed by the company’s Chief Financial Officer, G. Krishnan, dated July 27, 2026.

Trading window closure linked to the results

Alembic also reiterated that, under its code of conduct for regulating, monitoring, and reporting trading by designated persons and their immediate relatives, the trading window for dealing in the company’s securities was closed from July 1, 2026. The company said the trading window will reopen 48 hours after the declaration of the financial results. This is a standard compliance step around price-sensitive disclosures.

The latest reported base: Q4 FY26 performance

Ahead of Q1 FY27, the article cites Q4 FY26 as the most recently reported quarter and includes consolidated numbers. It states consolidated revenue from operations at ₹1,847.72 crore for Q4 FY26, with year-on-year growth of 4.41%, and consolidated net profit (PAT) at ₹202.70 crore, up 29.19% year-on-year from ₹156.89 crore in Q4 FY25.

Separately, the included earnings call material referenced revenue from operations of ₹1,838 crore for the quarter and reported profit after tax of ₹203 crore, and also highlighted certain items in the quarter, including an exceptional item of ₹24 crore and one-time tax adjustments of ₹101 crore (positive impact relating to MAT credit and tax regime-related adjustments). The same material cited EBITDA before R&D at ₹455 crore and gross margin at 71%, with core margins close to 25% compared with 24% in the prior-year quarter.

Dividend and record date noted for FY26

The article also notes that the board recommended a dividend of ₹12 per share (face value ₹2 each) for the financial year ended March 31, 2026. It states that July 29, 2026 was fixed as the record date to determine dividend eligibility for FY26. For investors, this is a key corporate action reference point around the end of the FY26 cycle.

Q1 FY27 numbers: pending approval, but estimates are circulating

Alembic’s Q1 FY27 unaudited financial results are pending board approval as of the disclosure, and the filing itself did not quantify Q1 FY27 performance. The article also includes a preview-style estimate range for Q1 FY27, presented as a revenue estimate of ₹1,677 to ₹1,930 crore and a PAT estimate of ₹174 to ₹221 crore, using a Q1 FY26 base of ₹1,717 crore revenue and ₹154 crore net profit. The same section cites a 12-month target range of ₹824 to ₹931.

Other corporate update referenced: USFDA tentative approval

The article also references an earlier update dated July 18, 2026, where Alembic said its partner NATCO Pharma Limited received tentative approval from the USFDA for Olaparib Tablets, 100 mg and 150 mg. The mention links to the company’s broader international business context, though it is separate from the Q1 FY27 results call announcement.

Stock and valuation snapshot included in the text

The article includes multiple market snapshots. One snapshot places Alembic shares at ₹824 with a market capitalisation of ₹16,169 crore and a price-to-earnings multiple of 24.1, alongside the cited 12-month target range of ₹824 to ₹931. Another snapshot mentions a price of ₹756, a market cap of ₹15.4K crore, and a P/E of 21.1. These figures are presented as contextual market references around the results season.

What to watch on August 4

The August 4 sequence is clear: the board meets to consider and approve Q1 FY27 unaudited results for the quarter ended June 30, 2026, and management interaction is scheduled for 5:30 PM IST. With Q4 FY26 numbers and FY26 dividend details already in the public domain, the Q1 FY27 outcome and management commentary are positioned as the next formal update for analysts and institutional investors. The company has also disclosed how participants can access the call and whom to contact for support.